TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
Status:
Completed
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of
single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with
UC. The relative bioavailability of tofacitinib released from TD-3504 compared to
co-administered oral heavy-labeled tofacitinib (15N2-tofacitinib) will also be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Theravance Biopharma Theravance Biopharma R & D, Inc.